Patients with early-stage HER2+ breast cancer could soon be offered less intensive treatment based on the results of a 27-gene panel, following findings from a meta-analysis.
Operator: Good afternoon. Thank you for attending today s Fourth Quarter and Full Year 2022 Gilead Sciences Earnings Conference Call. My name is Henna, and I will be your moderator for today s call.